To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer

NCT01284348 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

26

Enrollment

INDUSTRY

Sponsor class

Stopped Persistent low enrollment made study continuation no longer feasible

Conditions

Anemia
Carcinoma, Non-Small-Cell Lung
Carcinoma, Small-Cell Lung
Bladder Cancer
Cancer of Head and Neck
Uterine Cervical Cancer

Interventions

DRUG: Sotatercept 15 mg
DRUG: Sotatercept 30 mg

Sponsor

Merck Sharp & Dohme LLC